|Bid||66.16 x 800|
|Ask||66.16 x 900|
|Day's range||65.65 - 66.42|
|52-week range||57.17 - 74.12|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||20.24|
|Forward dividend & yield||2.92 (4.41%)|
|Ex-dividend date||14 Sept 2022|
|1y target est||N/A|
Yahoo Finance's Jared Blikre takes a look at how the Nasdaq 100 and major sectors are performing into the close.
Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.
Gilead Sciences (NASDAQ: GILD) stock was off to a good start this week, rising by more than 5% on Monday against the modest (0.4%) gain of the S&P 500 index. The prominent pharmaceutical company had some good news to impart about an important cancer drug. Gilead announced that morning that its breast cancer treatment Trodelvy recorded "statistically significant and clinically meaningful" results in a phase 3 clinical trial.